Sionna Therapeutics is trading 5.14% up now at $6.34, despite biotech and broader markets trading lower on September 1, 2026; no clear company-specific catalyst was identified.
- The latest major development remains the August 10 Phase 2a failure for SION-719.
- Sionna Therapeutics discontinued its add-on program.
- Those developments do not directly explain today’s gain.